Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04014205
Title A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Beijing InnoCare Pharma Tech Co., Ltd.
Indications

marginal zone B-cell lymphoma

chronic lymphocytic leukemia/small lymphocytic lymphoma

follicular lymphoma

mantle cell lymphoma

Therapies

Orelabrutinib

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.